A former FDA chemist pleaded guilty to charges that he tapped a confidential database to glean inside information that led to nearly $3.8 million in illicit stock trades.
Cheng Yi Liang admitted to using the database of new drug applications to suss out drugs that were about to be approved. Liang would then buy shares in the company that makes the drug, selling his stake after share prices jumped on news of FDA approval.